Effect of a SI-MMC on the IVR Rate After Ureteroscopy for UTUC

Trial Title: Effect of a SI-MMC on the IVR Rate After Ureteroscopy for UTUC

NCT ID: NCT05731622

Condition: Upper Urinary Tract Carcinoma

Conditions: Official terms:
Carcinoma

Conditions: Keywords:
Intravesical recurrence
Mitomycin C
Ureteroscopy

Study type: Observational [Patient Registry]

Overall status: Recruiting

Study design:

Time perspective: Prospective

Summary: The goal of this observational study is to evaluate the intravesical recurrence (IVR) rate after ureteroscopy (diagnostic or treatment) for upper tract urothelial carcinoma (UTUC) followed by an adjuvant single instillation of Mitomycin C (SI-MMC). The main question it aims to answer are: - What is the total and time to IVR after 2 years after ureteroscopy (diagnostic or treatment) for UTUC - How is the IVR compared with a historical cohort (no SI-MMC) - What is the time to IVR after 2 years in patients who subsequently received treatment by endoscopy vs. radical nephroureterectomy (RNU) - What is the additional value of a SI-MMC on time to IVR after RNU + adjuvant MMC in patients who were evaluated by ureteroscopy prior to RNU

Detailed description: The primary objective is to evaluate the IVR rate after ureteroscopy (diagnostic or treatment) followed by an single instillation of MMC (SI-MMC), in patients with clinically non-metastatic UTUC. The main question we aim to answer are: - What is the total and time to IVR after 2 years after ureteroscopy (diagnostic or treatment) for UTUC - How is the IVR compared with a historical cohort (no SI-MMC) - What is the time to IVR after 2 years in patients who subsequently received treatment by endoscopy vs. radical nephroureterectomy - What is the additional value of a SI-MMC on time to IVR after RNU + adjuvant MMC in patients who were evaluated by ureteroscopy prior to RNU. Secondary objectives include the evaluation of possible predictive factors for IVR rate. Study design: Multicentre, prospective cohort study in a clinical setting, Study population: All adult patients (age ≥18 years) with a (suspicion of a) urothelial carcinoma of the upper urinary tract undergoing ureteroscopy, either diagnostic or as endoscopic kidney sparing treatment, followed by a post-operative single instillation of Mitomycin C. Intervention: No intervention Main study parameters/endpoints: The primary endpoint of this study is the time to and total intravesical recurrences (histological proven) in the first 24 months following ureteroscopy (diagnostic or treatment) for UTUC followed a single instillation of Mitomycin C. Secondary Objective(s): to evaluate possible predictive factors for IVR rate looking at gender, tumour size, tumour focality, tumour location, postoperative stent placement, use of an ureteral access sheath, timing of administration of MMC, the performance of an endoscopic biopsy during ureteroscopy. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Investigations during follow-up include cystoscopy, ureteroscopy and CT-urography, which is in line with the standardized care and will not include additional investigations.

Criteria for eligibility:

Study pop:
Patients suspect of having non-metastatic UTUC

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - All patients suspect for having non-metastatic disease and planned for ureteroscopy (diagnostic or treatment) and adjuvant single instillation of Mitomycin C - Age ≥18 years - Written informed consent Exclusion Criteria: - History of histological proven urothelial carcinoma of the bladder, including carcinoma in situ - History of histological proven UTUC in the contralateral kidney - Concurrent bladder tumour found pre-operatively or per-operatively - Patients where it is not feasible to obtain histology by biopsies intra-operatively - Known Mitomycin C - Renal transplantation

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: AmsterdamUMC

Address:
City: Amsterdam
Country: Netherlands

Status: Recruiting

Contact:
Last name: Orlane Figaroa, MD
Email: o.j.figaroa@amsterdamumc.nl

Start date: February 2024

Completion date: September 2026

Lead sponsor:
Agency: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Agency class: Other

Source: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05731622